Literature DB >> 7807175

Pharmacokinetics of intrathecal 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rats.

T Y Huang1, N Arita, Y Ushio, T Hayakawa, K Yamada.   

Abstract

The pharmacokinetics of intrathecal 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) were studied in female Wistar rats by macroscopical autoradiography using 14C labeled ACNU. In normal rats, ACNU rapidly distributed in the subarachnoid space and ventricles after intracisternal administration. Diffusional transport into the brain tissue was limited to a depth of 1 or 2 mm from the cerebrospinal fluid (CSF) surface of the brain. Clearance of ACNU from the CSF space and brain was relatively fast and the half time of ACNU concentration at the cortical or ventricular surface was 10 min. In rats with leptomeningeal tumor induced by intracisternal inoculation of Walker 256 carcinosarcoma cells, the distribution pattern of ACNU after intracisternal administration was essentially the same as in normal rats until the tumor had grown in the subarachnoid space to form more than 10 or 20 layers of tumor cells. ACNU was distributed in the tumor as well. When the tumor had grown to form masses in the subarachnoid space, ACNU failed to penetrate to more than a depth of 1 or 2 mm from the tumor surface. Our results suggest that intrathecal ACNU administration may have no, or minor side effects on the brain and that it can eliminate floating or thin layered tumor cells in the subarachnoid space but not bulky tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807175     DOI: 10.1007/bf01053278

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

1.  Current status of intrathecal chemotherapy for human meningeal neoplasms.

Authors:  W A Bleyer
Journal:  Natl Cancer Inst Monogr       Date:  1977-12

2.  Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors.

Authors:  D S Fulton; V A Levin; P H Gutin; M S Edwards; M L Seager; J Stewart; C B Wilson
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 3.  Chemotherapy of malignant gliomas.

Authors:  Y Ushio; T Hayakawa; H Hasegawa; K Yamada; N Arita
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

4.  [Growth activity of meningeal carcinomatosis--immunohistochemical study using anti-BrdU monoclonal antibody].

Authors:  S Izumoto; N Arita; Y Ushio; T Hayakawa; T Yoshimine; T Y Huang; R Kuroda; H Mogami
Journal:  No To Shinkei       Date:  1988-02

5.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion.

Authors:  R G Blasberg; C Patlak; J D Fenstermacher
Journal:  J Pharmacol Exp Ther       Date:  1975-10       Impact factor: 4.030

6.  Meningeal carcinomatosis: development of an experimental model.

Authors:  Y Ushio; N L Chernik; J B Posner; W R Shapiro
Journal:  J Neuropathol Exp Neurol       Date:  1977 Mar-Apr       Impact factor: 3.685

7.  Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricular 3-[(4-amino-2-methyl-5-pyrimidinyl)ethyl]-1-(2-chloroethyl)-1-nitro soureas and other nitrosoureas in beagles.

Authors:  V A Levin; D Byrd; J Campbell; D D Giannini; J K Borcich; R L Davis
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

8.  [Intrathecal ACNU against malignant leptomeningeal tumors--toxicity and therapeutic effect in experimental animals].

Authors:  M Nagatani; N Arita; Y Ushio; T Hayakawa; H Tzuu-Yuan; T Yoshimine; S Mori; H Mogami
Journal:  No To Shinkei       Date:  1986-11

9.  Alteration of blood-CSF barrier by tumor invasion into the meninges.

Authors:  Y Ushio; K Shimizu; Y Aragaki; N Arita; T Hayakawa; H Mogami
Journal:  J Neurosurg       Date:  1981-09       Impact factor: 5.115

10.  [Clinical studies of meningeal gliomatosis].

Authors:  N Arita; Y Ushio; T Hayakawa; K Yamada; T Yoshimine; S Ko; H Mogami
Journal:  No To Shinkei       Date:  1984-08
View more
  2 in total

1.  A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

Authors:  Morris D Groves; Vinay K Puduvalli; Susan M Chang; Charles A Conrad; Mark R Gilbert; Ivo W Tremont-Lukats; Ta-Jen Liu; Pamela Peterson; David Schiff; Timothy F Cloughesy; Patrick Y Wen; Harry Greenberg; Lauren E Abrey; Lisa M DeAngelis; Kenneth R Hess; Kathleen R Lamborn; Michael D Prados; W K Alfred Yung
Journal:  J Neurooncol       Date:  2006-09-22       Impact factor: 4.130

2.  ACNU, MTX and 5-FU penetration of rat brain tissue and tumors.

Authors:  T Y Huang; N Arita; T Hayakawa; Y Ushio
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.